Petr Burkon, MD, PhD

Petr Burkon, M.D., Ph.D.

Masaryk Memorial Cancer Institute

Brno, Czech Republic

Petr Burkon, M.D., Ph.D. is a radiation oncology consultant and the Head of the Stereotactic Radiotherapy Programme at the Department of Radiation Oncology, Masaryk Memorial Cancer Institute (MMCI), in Brno, Czech Republic. He is also an assistant professor at the Faculty of Medicine, Masaryk University. Dr. Burkon received his medical degree from Masaryk University and earned his Ph.D. in Radiobiology from the University of Defence in Hradec Kralove.

With over 25 years of clinical experience, Dr. Burkon played a pioneering role in introducing stereotactic body radiation therapy (SBRT) in the Czech Republic, treating the first patient with SBRT in 2009. He led the first major Czech prospective study evaluating high-dose SBRT in patients with oligometastatic disease and has since treated more than 1,500 patients using this technique. His current research focuses on SBRT for oligometastatic disease and adjuvant partial breast irradiation using highly focused radiotherapy.

Dr. Burkon is the principal investigator of a national clinical trial evaluating stereotactic APBI in early-stage breast cancer and has contributed to several national and international studies in head and neck, breast, and lung cancer. He is a member of multiple tumor boards and oncology societies including ESTRO. His publication record includes over 40 papers with more than 350 citations, reflecting his commitment to advancing clinical research in precision radiotherapy.

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none